Ischaemic cardiovascular disease

Similar documents
NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)

Coronary heart disease and stroke

What s new in cardiovascular disease risk assessment and management for primary care clinicians

Diabetes follow-up: What are the PHO Performance Programme goals and how are they best achieved? Supporting the PHO Performance Programme

Cardiovascular Disease

Sheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)

Dr Joan Leighton. Professor Gerry Devlin. 14:00-14:55 WS #106: Whats Topical in Cardiology 15:05-16:00 WS #116: Whats Topical in Cardiology (Repeated)

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Downloaded from:

Quality Payment Program: Cardiology Specialty Measure Set

Guideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)

Coronary Heart Disease

Commissioning for value focus pack

Supplementary Online Content

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

Quality Payment Program: Cardiology Specialty Measure Set

CONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

NHS QIS National Measurement of Audit Acute Coronary Syndrome

In Pursuit of Excellence: The CheckPoint Journey

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

North Wales Cardiac Network Guidelines on oral antiplatelet therapy in cardiovascular disease

Malmö Diet and Cancer Study incl. CV-cohort. Cardiovascular Endpoints

Supplement materials:

Cancer and Heart/Stroke

The contractor establishes and maintains a register of patients with AF

The Muscatine Study Heart Health Survey

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

2017 MSSP Clinical Quality Measures

Quality Measures MIPS CV Specific

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

USRDS UNITED STATES RENAL DATA SYSTEM

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available?

GOVERNING BODY REPORT

Unstable angina and NSTEMI

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available?

The table below includes the quality measures an ACO is required to submit to CMS as a participant in an MSSP Track 3 ACO

Chapter 4: Cardiovascular Disease in Patients With CKD

Dr Chris Ellis. Consultant Cardiologist Auckland

Cancer and Heart/Stroke

Indicator Definitions

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Chapter 8: Cardiovascular Disease in Patients with ESRD

2016 Internal Medicine Preferred Specialty Measure Set

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Malmö Preventive Project. Cardiovascular Endpoints

Chapter 9: Cardiovascular Disease in Patients With ESRD

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Professor Norman Sharpe. Heart Foundation West Coast

Medical Declaration Form. Important information to read before completing the form:

Coronary Artery Disease Clinical Practice Guidelines

Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre

Cancer and Heart/Stroke

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Ischemic Heart Disease Interventional Treatment

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Proof of Concept: NHS Wales Atlas of Variation for Cardiovascular Disease. Produced on behalf of NHS Wales and Welsh Government

The Future of Cardiac Care: Managing Our Patients Together

Chapter 4: Cardiovascular Disease in Patients with CKD

(For items 1-12, each question specifies mark one or mark all that apply.)

2017 CMS Web Interface Reporting

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

Cardiovascular disease profile

This information explains the advice about the care and treatment of people with stable angina that is set out in NICE clinical guideline 126.

ASPIRIN AND VASCULAR DISEASE

Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes

2016 General Practice/Family Practice Preferred Specialty Measure Set

Dianne Johnson / Lee Panter / Sarah McNulty

Downloaded from:

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

Stroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013

Long-Term Management Of the ACS Patient: State-of-the-Art. Kim Newlin, CNS, NP-C, FPCNA Sutter Roseville Medical Center Roseville, CA

LOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING

DECLARATION OF CONFLICT OF INTEREST

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

Chapter 4: Cardiovascular Disease in Patients With CKD

Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126

JAWDA Quarterly Waiting Time Guidelines for (Specialized and General Hospitals)

More honoured in the breach

Quality and Outcomes Framework guidance for GMS contract 2009/10. Delivering investment in general practice

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

The following principles relating to the Quality and Outcomes Framework (QOF) were agreed by the negotiators.

JUSTUS WARREN TASK FORCE MEETING DECEMBER 05, 2012

Cardiovascular disease PCT health profile. County Durham. Contents

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Practice-Level Executive Summary Report

NATIONAL QUALITY FORUM

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome

(i) This FAQ does not deal with clinical issues (eg What is the definition of a stroke unit? or

Cardiovascular risk reduction in diabetes Lipids (NICE CG181)

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members

SCORES FOR 4 TH QUARTER, RD QUARTER, 2014

Do Not Cite. Draft for Work Group Review.

Transcription:

Ischaemic cardiovascular disease What are the PHO performance programme indicators and how are they best achieved? 40 BPJ Issue 36

Supporting the PHO Performance Programme The PHO Performance Programme The PHO Performance Programme was established to reduce disparities and improve health outcomes for all people using primary healthcare services in New Zealand. A number of priority health areas have been identified and performance indicators created which can be measured against ideal targets. Incentives, in the form of financial payment to the PHO, encourage performance. For most of the indicators, the closer the PHO is to achieving the target, the greater the proportion of the payment is made. Performance indicators may change from year to year and some indicators are provided for information only and do not qualify for a payment. Table 1 lists the indicators that are currently funded. PHO performance indicator for ischaemic cardiovascular disease Indicator definition The PHO performance indicator and target for ischaemic cardiovascular disease is: For 90% of enrolled patients aged between 30 and 79 years with ischaemic cardiovascular disease, to have been identified and coded within their patient notes. The denominator for this indicator (i.e. what the results are compared against) is the estimated prevalence Table 1: Funded PHO Performance Indicators for the period commencing 1 January, 2011 Chronic conditions Infectious disease Financial Cervical cancer screening Breast cancer screening Ischaemic cardiovascular disease detection Cardiovascular disease risk assessment Diabetes detection Diabetes follow-up after detection Smoking status Influenza vaccine in people aged over 65 years Age appropriate vaccinations for children aged two years GP referred laboratory expenditure GP referred pharmaceutical expenditure BPJ Issue 36 41

of ischaemic cardiovascular disease within the PHO population. This is calculated by adjusting the national prevalence of ischaemic cardiovascular disease to the age, gender and ethnicity variables of the PHO population. This indicator makes up a total of 9% of a PHO s performance payment (3% for achieving the target in the total population and 6% for achieving the target in the high needs population). * * High needs is defined as Māori and Pacific peoples and people living in New Zealand Deprivation Decile 9 or 10 socioeconomic areas (most deprived) What is defined as ischaemic cardiovascular disease? For the purpose of the indicator, ischaemic cardiovascular disease is defined as a medical diagnosis, either current or in the past, of one or more of the following conditions: Ischaemic heart disease acute coronary syndrome, angina, percutaneous coronary intervention (PCI), coronary arterial bypass graft (CABG), myocardial infarction Peripheral vascular disease atherosclerosis, aortic aneurysm Cerebrovascular disease stroke and transient ischaemic attack (TIA) N.B. Cardiac failure is not included as an indicator due to variable access to diagnostic testing. In addition, not all cardiac failure is caused by ischaemic heart disease. A G3 Read code detects all coded current and past cases of ischaemic heart disease. A computerised search using G3 automatically captures all lower codes such as G30 for myocardial infarction and G33 for angina. Cardiac procedures such as bypass surgery or angioplasty are listed under Read code 79 (although the patient should also have an existing G3 root code for the condition that required them to undergo the procedure). A G6 Read code detects all coded current and past cases of cerebrovascular disease, but does not differentiate between atherosclerotic disease and cerebral haemorrhage. A G70-73 Read code detects all coded current and past cases of peripheral vascular disease. In these two cases, specified Read codes are excluded from counting towards the PHO Performance Programme target (Table 2). The use of the code G70 relates to the Read term atherosclerosis, which in itself provides little clinical context. To record the presence of peripheral vascular disease we suggest the use of the G73z code. This covers the performance programme definition and provides better clinical context for clinicians. For a list of all Read codes that are identified for the PHO Performance Programme see Code Mappings for data transfer specification and clinical performance indicator data format standard document. pages 17-27, available from: www.dhbnz.org.nz/site/sig/pho/ Technical-Documents.aspx How should a diagnosis of ischaemic cardiovascular disease be recorded? The diagnosis of ischaemic cardiovascular disease needs to be recorded in a way that is retrievable. This means that an appropriate read code should be entered on the electronic patient record in the practice management system (PMS). Any qualifying Read code matched to a qualifying patient will be counted, regardless of when it was recorded. Previously, some PMS had an arbitrary ten-year look-back cut-off built into their queries but this limit has now been removed. The PMS error will have adversely affected the levels reported by the PHO Performance Programme prior to April 2011 when the patch was released. 42 BPJ Issue 36

Table 2: Read codes for ischaemic cardiovascular disease for the PHO Performance Programme Description Root Read code Excluded codes Ischaemic heart disease Heart failure Heart disease (not otherwise specified) Cerebrovascular disease: Cerebral arterial occlusion Transient cerebral ischaemia Atherosclerosis G3... G58.. G5y.. G6... G64.. G65.. G70.. G60.. G61.. G62.. G669. G6731 G674. G675. G676. Aortic aneurysm G71.. G717. Other aneurysm G72.. Other peripheral vascular disease G73.. G730. G731. G73y2 G73y4 G73y5 G73y6 G73y7 G73y8 G73yZ Cardiac procedures 792.. Endarterectomy carotid artery 7A204 Ways to optimise coding for ischaemic CVD coding within the practice To decide which approach to ischaemic cardiovascular disease coding is best for your practice, first consider who within the practice might have the skills and time available to review the various sources where information concerning ischaemic CVD can be retrieved. Sources include: 1. Letters from secondary care, e.g. outpatient clinics, surgical operation notes, inpatient admission letters. 2. Previous medical records (usually in the form of paper-based patient notes), especially from patients that are newly registered with the practice. 3. Audits on medicines that suggest a diagnosis of ischaemic cardiovascular disease such as: antianginals (glyceryl trinitrate, isosorbide, nicorandil and perhexiline), dipyridamole and clopidogrel. N.B. Some medicines such as warfarin, aspirin or statins would not be appropriate for this audit as they may be used for conditions others than ischaemic cardiovascular disease, e.g. primary prevention of cardiovascular disease, atrial fibrillation. Read codes can be added to patient notes within the PMS, at the time of the consultation. When relevant letters from secondary care arrive at the practice, Read codes can be entered directly by the GP reviewing the letter, or by highlighting or underlining any keywords on the letter for another staff member to enter the code. Check Read codes whenever doing a repeat prescription, and if the code is not there, add it to the list of classifications. When adding a classification it is useful to tick both longterm and add to patient history on the classifications template in the PMS (if available). This will assist when writing referral letters in the future. BPJ Issue 36 43

Establish policies within the practice to ensure consistency, accuracy and completeness of disease classification recording and clinical event coding. Missing medical history? Some patients have little or no recorded medical history, e.g. they may have immigrated to New Zealand or spent some time out of New Zealand, or their old notes (or parts of their record) may have become lost when transferring from one practice to another. When asking these patients about their previous medical history, it may be useful to enquire specifically about whether they have ever had a heart attack, stroke, mini-stroke or any heart surgery as these are terms that most people are familiar with. Also consider opportunistically asking this same question of any patients aged over 50 years, to potentially identify ischaemic cardiovascular disease that is not recorded on the medical record held in primary care. What are the benefits of coding ischaemic cardiovascular disease? The main benefit of identifying and coding patients with ischaemic cardiovascular disease is in creating the best opportunity for secondary prevention. Another important benefit is patient safety it is easy for other doctors in the practice and locums to know what health problems the patient has when their primary doctor is absent. Accurate coding also ensures that any referral includes this information, which is particularly important if referring the patient for a surgical intervention. General Practice disease registers CVD Consistent coding across general practice enables the development of disease registers. Disease registers group together long-term medical conditions with similar precursor risk factors and secondary preventative measures. Registers can be used to help to plan and organise preventative programmes and appropriate care, monitor the health of the practice population, facilitate audit and review clinical practice. It is important to understand the difference between disease codes and health event codes. For example, a patient with an inferiolateral myocardial infarct could have the following codes: Ischaemic heart Disease G3.00 disease classification Code Acute inferolateral G302.00 Health event code infarction The G3 code should be linked to consultations where this specific disease area has been covered. This ensures that the overriding disease class code remains at the top of the classification list in the PMS. Resource: DHBNZ. PHO Performance programme. Indicator definitions. Version 5. Available from: www.dhbnz.org.nz/ Site/SIG/pho/Operational-Documents.aspx 44 BPJ Issue 36